Your browser doesn't support javascript.
loading
Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis.
Burgert-Brucker, Clara R; Zoerhoff, Kathryn L; Headland, Maureen; Shoemaker, Erica A; Stelmach, Rachel; Karim, Mohammad Jahirul; Batcho, Wilfrid; Bougouma, Clarisse; Bougma, Roland; Benjamin Didier, Biholong; Georges, Nko'Ayissi; Marfo, Benjamin; Lemoine, Jean Frantz; Pangaribuan, Helena Ullyartha; Wijayanti, Eksi; Coulibaly, Yaya Ibrahim; Doumbia, Salif Seriba; Rimal, Pradip; Salissou, Adamou Bacthiri; Bah, Yukaba; Mwingira, Upendo; Nshala, Andreas; Muheki, Edridah; Shott, Joseph; Yevstigneyeva, Violetta; Ndayishimye, Egide; Baker, Margaret; Kraemer, John; Brady, Molly.
Afiliação
  • Burgert-Brucker CR; Global Health Division, RTI International, Washington, DC, United States of America.
  • Zoerhoff KL; Global Health Division, RTI International, Washington, DC, United States of America.
  • Headland M; Global Health Division, RTI International, Washington, DC, United States of America.
  • Shoemaker EA; Global Health, Population, and Nutrition, FHI 360, Washington, DC, United States of America.
  • Stelmach R; Global Health Division, RTI International, Washington, DC, United States of America.
  • Karim MJ; Global Health Division, RTI International, Washington, DC, United States of America.
  • Batcho W; Department of Disease Control, Ministry of Health and Family Welfare, Dhaka, Bangladesh.
  • Bougouma C; National Control Program of Communicable Diseases, Ministry of Health, Cotonou, Benin.
  • Bougma R; Lymphatic Filariasis Elimination Program, Ministère de la Santé, Ouagadougou, Burkina Faso.
  • Benjamin Didier B; Lymphatic Filariasis Elimination Program, Ministère de la Santé, Ouagadougou, Burkina Faso.
  • Georges N; National Onchocerciasis and Lymphatic Filariasis Control Program, Ministry of Health, Yaounde, Cameroon.
  • Marfo B; National Onchocerciasis and Lymphatic Filariasis Control Program, Ministry of Health, Yaounde, Cameroon.
  • Lemoine JF; Neglected Tropical Diseases Programme, Ghana Health Service, Accra, Ghana.
  • Pangaribuan HU; Ministry of Health, Port-au-Prince, Haiti.
  • Wijayanti E; National Institute Health Research & Development, Ministry of Health, Jakarta, Indonesia.
  • Coulibaly YI; National Institute Health Research & Development, Ministry of Health, Jakarta, Indonesia.
  • Doumbia SS; Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Bamako, Mali.
  • Rimal P; Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Bamako, Mali.
  • Salissou AB; Epidemiology and Disease Control Division, Department of Health Service, Kathmandu, Nepal.
  • Bah Y; Programme Onchocercose et Filariose Lymphatique, Ministère de la Santé, Niamey, Niger.
  • Mwingira U; National Neglected Tropical Disease Program, Ministry of Health and Sanitation, Freetown, Sierra Leone.
  • Nshala A; Neglected Tropical Disease Control Programme, National Institute for Medical Research, Dar es Salaam, Tanzania.
  • Muheki E; IMA World Health/Tanzania NTD Control Programme, Uppsala University, & TIBA Fellow, Dar es Salaam, Tanzania.
  • Shott J; Programme to Eliminate Lymphatic Filariasis, Ministry of Health, Kampala, Uganda.
  • Yevstigneyeva V; Division of Neglected Tropical Diseases, Office of Infectious Diseases, Bureau for Global Health, USAID, Washington, DC, United States of America.
  • Ndayishimye E; Division of Neglected Tropical Diseases, Office of Infectious Diseases, Bureau for Global Health, USAID, Washington, DC, United States of America.
  • Baker M; Global Health, Population, and Nutrition, FHI 360, Washington, DC, United States of America.
  • Kraemer J; Global Health Division, RTI International, Washington, DC, United States of America.
  • Brady M; Global Health Division, RTI International, Washington, DC, United States of America.
PLoS Negl Trop Dis ; 14(6): e0008301, 2020 06.
Article em En | MEDLINE | ID: mdl-32479495
ABSTRACT
Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments. The first assessments recommended by the World Health Organization (WHO) are sentinel and spot-check sites-referred to as pre-transmission assessment surveys (pre-TAS)-in each implementation unit after MDA. If pre-TAS shows that prevalence in each site has been lowered to less than 1% microfilaremia or less than 2% antigenemia, the implementation unit conducts a TAS to determine whether MDA can be stopped. Failure to pass pre-TAS means that further rounds of MDA are required. This study aims to understand factors influencing pre-TAS results using existing programmatic data from 554 implementation units, of which 74 (13%) failed, in 13 countries. Secondary data analysis was completed using existing data from Bangladesh, Benin, Burkina Faso, Cameroon, Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. Additional covariate data were obtained from spatial raster data sets. Bivariate analysis and multilinear regression were performed to establish potential relationships between variables and the pre-TAS result. Higher baseline prevalence and lower elevation were significant in the regression model. Variables statistically significantly associated with failure (p-value ≤0.05) in the bivariate analyses included baseline prevalence at or above 5% or 10%, use of Filariasis Test Strips (FTS), primary vector of Culex, treatment with diethylcarbamazine-albendazole, higher elevation, higher population density, higher enhanced vegetation index (EVI), higher annual rainfall, and 6 or more rounds of MDA. This paper reports for the first time factors associated with pre-TAS results from a multi-country analysis. This information can help countries more effectively forecast program activities, such as the potential need for more rounds of MDA, and prioritize resources to ensure adequate coverage of all persons in areas at highest risk of failing pre-TAS.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Filariose Linfática / Transmissão de Doença Infecciosa / Filaricidas Tipo de estudo: Clinical_trials / Etiology_studies / Evaluation_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Filariose Linfática / Transmissão de Doença Infecciosa / Filaricidas Tipo de estudo: Clinical_trials / Etiology_studies / Evaluation_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article